OARS funding Cancer

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high-value informatics research resources to serve current and emerging needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on supporting activities necessary for improved user experience and availability of existing, widely-adopted informatics tools and resources.  This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justifications for why the research resource should be maintained and how it has benefited and will continue to benefit the cancer research field.  In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and/or deep engagement between the resource and the targeted research community should be described.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as the initial development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process should be included.

The National Institutes of Health (NIH) seeks input on the restructuring of the NIH grant application instructions. We invite comments from any interested parties. We encourage feedback from PD/PIs, Administrative Offices, Offices of Sponsored Programs, Systems Administrators, and any other parties that rely on our application submission information.

The University of Chicago is offering talented individuals from traditionally underrepresented populations an expenses-paid opportunity to explore graduate education at the University of Chicago. Join us for a weekend of graduate admissions workshops, presentations by world-renowned faculty and their graduate students, and informal socials. Receive advice on submitting a competitive application to graduate programs and learn how to develop your own career as a scientist, academic, or professional.

The Idea Development Award promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths from lung cancer. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. Submissions from and partnerships with investigators at military treatment facilities, military labs, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged. New Investigators: The FY15 Idea Development Award mechanism encourages applications from independent investigators in the early stages of their careers (i.e., within 10 years of their first faculty appointment, or equivalent). The New Investigator category is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators. Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately. Principal Investigators (PIs) using the New Investigator category are strongly encouraged to strengthen their applications by collaborating with investigators experienced in lung cancer research and/or possessing other relevant expertise. It is the responsibility of the applicant to describe how the included collaboration will augment the PI's expertise to best address the research question. All applicants for the New Investigator category must meet specific eligibility criteria as described in Section I.D., Eligibility Information.

The Career Development Award supports early-career, independent investigators to conduct impactful research under the mentorship of an experienced lung cancer researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of lung cancer research. This award is intended to support impactful research projects with an emphasis on discovery. Submissions from and partnerships with investigators at military treatment facilities, military labs, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged. Key elements of this award are as follows: * Principal Investigator (PI): PIs must be research- or physician-scientists at an early stage of their independent research careers. PIs must be within 5 years of their first faculty appointment (or equivalent), and exhibit a strong desire to pursue a career in lung cancer research. * Mentorship: The mentor must be an experienced lung cancer researcher as demonstrated by a strong record of funding and publications in lung cancer research. In addition, the mentor must demonstrate a commitment to developing the PI's career in lung cancer research. * Career Development: A Career Development Plan is required and should be prepared with appropriate guidance from the mentor. A clearly articulated strategy for acquiring the necessary skills, competence, and expertise to have a career at the forefront of lung cancer research should be included. The plan should outline how the PI will gain experience and training in lung cancer research. Because career development is the focus of this award, the PI's institution must demonstrate a commitment to the PI through a minimum of 40% protected time for the proposed research, though more protected time is highly desirable. * Impact: Research that has high potential impact may lead to major advancements and significantly accelerate progress toward eradicating death

The National Cancer Institute (NCI) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in all areas of cancer research. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (biomedical, behavioral, or clinical).

Alliance for Cancer Gene Therapy, Inc. (ACGT) funds research aimed at furthering the development of cell and gene therapy approaches to the treatment of cancer. To this end, ACGT offers awards in Clinical Translation of Cell and Gene Therapy for Cancer, to qualified scientists at the assistant professor level and above. This award is specifically for those conducting Cell and Gene Therapy Research for sarcoma and is entitled, The Wendy Walk/ACGT Sarcoma Research Grant.

This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research.

The Stand Up To Cancer (SU2C),  Innovative Research Grant is open to early-career scientists whose novel, high-risk, high-reward cancer research proposals have significant potential for translational application and hold great promise for advancing SU2C's overarching goal of improving and saving the lives of patients. Letters of Intent may focus on any discipline within basic, translational, or clinical cancer research. Projects that are currently supported by NIH R01 grants or the equivalent will not be accepted.

This funding opportunity announcement (FOA) is a part of cancer genomics programs supported by the National Cancer Institute (NCI) and managed by its Center for Cancer Genomics (CCG). The overall goal of all CCG programs is to help elucidate the mechanisms of cancer initiation and evolution, as well as resistance to therapy by means of genomic characterization of well-annotated, high quality tumor samples. 

The NIH Directors Early Independence Award Program supports exceptional investigators who wish to pursue independent research directly after completion of their terminal doctoral/research degree or clinical residency, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career.

This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for imaging, detecting, diagnosing, preventing, and/or treating cancers in humans living in LMICs.

This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for imaging, detecting, diagnosing, preventing, and/or treating cancers in humans living in LMICs.

The purpose of this Notice is to inform new NIH applicants, their mentors, and grant administrators at their institution about two upcoming webinars the NIH Center for Scientific Review (CSR) is hosting in November 2015.  These webinars are designed to give participants useful insights into our application submission and peer review processes.  CSR is the portal for NIH grant applications and their review for scientific and technical merit.

Through the program, the center will award three grants of up to $60,000 each to promising laboratory and clinical scientists interested in pursuing a career as an independent investigator in ovarian cancer research. Funds are for direct costs only; institutional overhead and indirect costs will not be included in the award.

The annual Pancreatic Cancer Action Network-AACR Pathway to Leadership grant program represents a joint effort to ensure the future leadership of pancreatic cancer research by supporting outstanding early career investigators, beginning in their postdoctoral research positions and continuing through their successful transition to independent research. A five-year grant of up to $600,000 will be awarded to support a highly promising postdoctoral or clinical research fellow who is in the mentored research phase and ready to transition to an independent research career.

The annual Pancreatic Cancer Action Network-AACR Pathway to Leadership grant program represents a joint effort to ensure the future leadership of pancreatic cancer research by supporting outstanding early career investigators, beginning in their postdoctoral research positions and continuing through their successful transition to independent research. A five-year grant of up to $600,000 will be awarded to support a highly promising postdoctoral or clinical research fellow who is in the mentored research phase and ready to transition to an independent research career.

The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue support for the Childhood Cancer Survivor Study (CCSS) as a resource enabling broad studies on the long-term effects of cancer and its associated therapies on survivors of pediatric cancers. 

The goal of this Funding Opportunity Announcement (FOA) is to facilitate the planning, designing and initial research focus of Regional Centers of Research Excellence (RCRE) for non-communicable disease, including cancer, in low and middle-income countries (LMICs). 

Founded in 1996, the Marsha Rivkin Center for Ovarian Cancer Research provides funding in a range of areas, including funding for innovative pilot studies, scholar grants to up-and-coming investigators, early detection screening for ovarian cancer, and research symposia on ovarian cancer.